Stocktoria

VASO Corp VASO

OTC · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 1988-12-01 · LEI

VASO Corp (VASO) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $89.1M at a 1.8% net margin.

$0.30 high · $0.11 low · daily closes (~2y) · hover for date & price
37/100
Stocktoria Quality Score · grade D
6/9
Piotroski F — financial health
0.72
Altman Z″ — distress risk · distress
—
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 4 4 3 5 8 8 5 3 6 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$0.30 as of 2026-09-01 · +150% 1y
$0.11$0.3052-wk
Market cap USD$33M
P / E21.3×
Net margin 5y avg6.2%
Return on equity 5y avg26.3%
Beta0.57
Employees282
Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 2036 companies

Piotroski Fstronger than 78%
Net marginstronger than 58%
Return on equitystronger than 66%
Revenue growthstronger than 43%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.246
Retained earnings / assets-0.368
EBIT / assets-0.033
Equity / liabilities0.499

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
VASOVASO Corp6/90.7221.3+2.7%
CBLLCeribell, Inc.3/93.97—+36.1%
BLFSBIOLIFE SOLUTIONS INC6/910.32—+28.9%
ELMDElectromed, Inc.6/910.9930.9+15.3%
FOCLEDAP TMS SA3/9-5.4—+1.6%
OMOutset Medical, Inc.6/9-9.87—+5.1%
IRIXIRIDEX CORP4/9-8.01—+8.2%

All Manufacturing companies →

About VASO Corp

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. It operates in three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed network infrastructure, such as routers, switches, and other core equipment; managed network transport; and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare, Inc. (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

FAQ

Is VASO financially healthy?

VASO Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does VASO pay a dividend?

No, VASO Corp does not currently pay a dividend.

How profitable is VASO?

In FY2025, VASO Corp had a net margin of 1.8% and a return on equity of 5.3%.

Is VASO overvalued or undervalued?

VASO Corp trades at about 30.0× trailing earnings — above its 10-year norm (10-year range 3.5×–18.0×, median 12.5×). Stocktoria reports the data, not buy/sell advice.

Is VASO a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on VASO Corp: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 21.3×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.